


Double-blind, Placebo-controlled, randomized, multicenter study comparing Tafasitamab and Lenalidomide in addition to R-CHOP with Placebo and R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed DLBCL



The efficacy and safety of the investigational compound discussed^a have not been established. There is no guarantee that this compound^a will become commercially available for the use(s) under investigation.

For more information, visit [IncyteClinicalTrials.com](https://www.incyteclinicaltrials.com), contact us at +800 00027423 or by email at clintrials@incyte.com, or click on the QR code on the right to visit the trial on clinicaltrials.gov

For reporting adverse events, contact eumedinfo@incyte.com or +49 8007239013



^a Tafasitamab
aaIPI: age-adjusted IPI; BIRC: Blinded Independent Central Review; CNS: Central Nervous System; CR: Complete Response; DLBCL: Diffuse Large B Cell Lymphoma; ECOG PS: Eastern Cooperative Oncology Group Performance Status; EFS: Event-free Survival; EOT: End of Treatment; INV: Investigator; IPI: International Prognostic Index; IV: Intravenous; LVEF: Left Ventricle Ejection Fraction; MRD: Minimal Residual Disease; ORR: Overall Response Rate; OS: Overall Survival; PFS: Progression-free Survival; PO: Peroral; R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin (Hydroxydaunomycin), Vincristine (Oncovin), Prednisone; <https://clinicaltrials.gov/ct2/show/NCT04824092>; Accessed 11 June 2021